P06 The effectiveness of different biologic classes when used as first-line systemic treatment for psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register

Clicks: 1
ID: 318460
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #284 of 304 articles by views in the british journal of dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 304 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction and aims In the UK, biologics for moderate-to-severe psoriasis are typically initiated only after failure or intolerance of conventional systemic therapies. This stepwise approach may unnecessarily delay access to effective treatment, potentially increasing cumulative life-course impairment, comorbidity burden, and reducing quality of life. Methods This study used data from the British Association of Dermatologists Biologics and Immunomodulators Register from September 2007 to December 2024. We compared the effectiveness of initiating first-line systemic therapy with biologics from different classes vs. standard care, defined as starting with a nonbiologic systemic therapy with possible subsequent switching to a biologic. We included adults (≥ 18 years) with moderate-to-severe psoriasis [baseline Psoriasis Area and Severity Index (PASI) ≥ 10] and no prior systemic therapy at registration. PASI trajectories over 5 years were modelled using mixed-effects repeated measures, adjusting for baseline and time-varying covariates. The probability of achieving complete skin clearance (PASI = 0) was estimated using marginal structural models with stabilized inverse probability weighting to address time-varying confounding. Results A total of 3702 patients were included: 3368 initiated standard of care; 167 started a tumour necrosis factor (TNF)-α inhibitor (i); 56 an interleukin (IL)-12/23i; 51 an IL-17i; and 60 an IL-23i. After 1 year, predicted mean PASI [95% confidence interval (CI)] was 6.7 (95% CI 6.3–7.1) for standard care, 3.1 (95% CI 2.3–2.8) for TNF-αi, 2.1 (95% CI 1.2–2.9) for IL-12/23i, 2.6 (95% CI 0.8–4.3) for IL-17i, and 0.4 (95% CI 0.0–0.7) for IL-23i. Overall, 5-year cumulative PASI 0 rates were 32.1% for standard care, 47.8% for TNFαi, 48.2% for IL-12/23i, 67.0% for IL-17i, and 91.2% for IL-23i. Compared with standard care, all biologic classes showed significantly higher probability of achieving PASI 100: TNFαi hazard ratio (HR) 2.16 (95% CI 1.63–2.87), IL-12/23i HR 2.65 (95% CI 1.73–4.06), IL-17i HR 3.30 (95% CI 1.98–5.48), and IL-23i HR 7.45 (95% CI 5.25–10.58). Conclusions Our results suggest that initiating a biologic as the first systemic treatment for psoriasis improves treatment effectiveness compared with standard of care.
Reference Key
openalex_W7165638495 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Duc Binh Phan, Philip Laws, C. Smith, Christopher E M Griffiths, Brian Kirby, Olivia Hughes, G Rogers, Oras Alabas, Mark Lunt, Richard B Warren, Zenas Z N Yiu
Journal the british journal of dermatology
Year 2026
DOI
10.1093/bjd/ljag151.047
URL
https://doi.org/10.1093/bjd/ljag151.047
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.